|
Q1 FY2026
As of Sep 30, 2025
|
Q4 FY2025
As of Jun 30, 2025
|
Q3 FY2025
As of Mar 31, 2025
|
Q2 FY2025
As of Dec 31, 2024
|
Q1 FY2025
As of Sep 30, 2024
|
Q3 FY2024
As of Mar 31, 2024
|
Q2 FY2024
As of Dec 31, 2023
|
Q1 FY2024
As of Sep 30, 2023
|
Q4 FY2023
As of Jun 30, 2023
|
Q3 FY2023
As of Mar 31, 2023
|
Q2 FY2023
As of Dec 31, 2022
|
Q1 FY2023
As of Sep 30, 2022
|
Q4 FY2022
As of Jun 30, 2022
|
Q3 FY2022
As of Mar 31, 2022
|
Q2 FY2022
As of Dec 31, 2021
|
Q1 FY2022
As of Sep 30, 2021
|
Q4 FY2021
As of Jun 30, 2021
|
Q3 FY2021
As of Mar 31, 2021
|
Q2 FY2021
As of Dec 31, 2020
|
Q1 FY2021
As of Sep 30, 2020
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| CURRENT ASSETS | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||
| Prepaid expenses | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| NONCURRENT ASSETS | ||||||||||||||||||||
| Patent, net | ||||||||||||||||||||
| Film costs | ||||||||||||||||||||
| Deposits | ||||||||||||||||||||
| Equity investment | ||||||||||||||||||||
| Total noncurrent assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND SHAREHOLDERS’ DEFICIT | ||||||||||||||||||||
| CURRENT LIABILITIES | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued expenses | ||||||||||||||||||||
| Related party loans, current | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total related party loans, current | ||||||||||||||||||||
| Notes payable, current | ||||||||||||||||||||
| Other current liabilities | ||||||||||||||||||||
| Note payable AIP | ||||||||||||||||||||
| Advance - related party | ||||||||||||||||||||
| Accrued interest | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Related party loans, non-current | ||||||||||||||||||||
| Related party loans, non-current | ||||||||||||||||||||
| Notes payable, non-current | ||||||||||||||||||||
| Total noncurrent liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| SHAREHOLDERS’ DEFICIT | ||||||||||||||||||||
| Preferred Stock, Value, Issued | ||||||||||||||||||||
| Escrow Shares (1) | ||||||||||||||||||||
| Escrow Shares (1) (2) | ||||||||||||||||||||
| Common stock, par value of $0.001; 547,500,000 shares authorized; 109,695,876 issued and outstanding as of September 30, 2025 and June 30, 2025 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total shareholders’ deficit | ||||||||||||||||||||
| Total liabilities & shareholders’ deficit |
Loading...
